康希諾及藥明系股份倒跌8%-8.6% 以色列數據確認輝瑞疫苗保護力高
以色列研究數據顯示接種兩劑輝瑞/BioNTech新冠疫苗後感染風險大降95.8%,醫藥股今天普遍下滑,尤其是藥明生物(02269.HK)繼上周二升至128.9元紀錄高遇阻掉頭向下,最近五個月交易日僅上周五反彈,其餘均跌兼已失守10天及20天線,今天股價低見107元,現造108元,急挫7.9%;非藍籌藥明康德(02359.HK)也由高位203元,掉頭倒跌8.1%報183.1元。
同為藍籌石藥(01093.HK)及中生製藥(01177.HK)今早高開見8.8元7.75元遇阻,掉頭倒跌3.1%及2.8%,報8.37元及7.42元,後者股價一舉失守50天、20天及10天線。
康希諾生物(06185.HK)由高位三連跌,報350.8元,挫8.6%。信達生物(01801.HK)反覆跌6.1%報87元。微創醫療(00853.HK)倒跌6.9%報47.8元,股價失守50天線(49.3元)。復星醫藥(02196.HK)由高位六連跌,報37.8元,反覆續跌2.8%。威高股份(01066.HK)反覆續跌5.5%報14.08元。
相反,三生製藥(01530.HK)五連漲,承上周五升破牛熊線(8.62元)勢,今天高見9.33元,創逾五個月高,現造9.01元,續升2.7%。四環醫藥(00460.HK)由逾三年高位掉頭三連吐守穩10天線,今天股價高見2.85元,暫受制上周所創高位2.91元,現造2.75元,回升5%。神威藥業(02877.HK)升4.2%曾高見6.05元創逾11個月高。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.